Literature DB >> 7985575

An experimental arteriovenous malformation model in swine: anatomic basis and construction technique.

T F Massoud1, C Ji, F Viñuela, G Guglielmi, J Robert, G R Duckwiler, Y P Gobin.   

Abstract

We assessed the feasibility of creating an experimental arteriovenous malformation model in swine by diverting and increasing blood flow through bilateral retia mirabilia. This was achieved by surgical formation of a large right-sided carotid-jugular fistula, in combination with endovascular occlusion of several neck arteries ipsilateral to the fistula. Using this technique, 11 of 13 swine demonstrated an acute-phase angiographic simulation of an arteriovenous malformation. There was rapid circulatory diversion from the left ascending pharyngeal artery ("feeder"), across both retia ("nidus"), and fast retrograde flow into the right ascending pharyngeal and common carotid arteries ("draining vein") toward the fistula. The relevant vascular anatomy of the swine head and neck is outlined, and steps in the construction of this arteriovenous malformation model are detailed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7985575      PMCID: PMC8334424     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  25 in total

1.  Experimental arteriovenous malformations modeling in laboratory sheep versus swine.

Authors:  T F Massoud
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 3.825

Review 2.  Interventional neuroradiology.

Authors:  C M Strother
Journal:  AJNR Am J Neuroradiol       Date:  2000-01       Impact factor: 3.825

3.  Histopathologic characteristics of a chronic arteriovenous malformation in a swine model: preliminary study.

Authors:  T F Massoud; H V Vinters; K H Chao; F Viñuela; R Jahan
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

Review 4.  The ascending pharyngeal artery: branches, anastomoses, and clinical significance.

Authors:  Lotfi Hacein-Bey; David L Daniels; John L Ulmer; Leighton P Mark; Michelle M Smith; James M Strottmann; Douglas Brown; Glenn A Meyer; Phillip A Wackym
Journal:  AJNR Am J Neuroradiol       Date:  2002-08       Impact factor: 3.825

5.  Basics and Principles in the Application of Onyx LD Liquid Embolic System in the Endovascular Treatment of Cerebral Arteriovenous Malformations.

Authors:  R Siekmann
Journal:  Interv Neuroradiol       Date:  2005-10-27       Impact factor: 1.610

6.  Temporal resolution of dynamic angiography using flat panel volume CT: in vivo evaluation of time-dependent vascular pathologies.

Authors:  R Gupta; A Mehndiratta; A P Mitha; M Grasruck; C Leidecker; C Ogilvy; T J Brady
Journal:  AJNR Am J Neuroradiol       Date:  2011-08-11       Impact factor: 3.825

7.  Liquid 2-poly-hydroxyethyl-methacrylate embolization of experimental arteriovenous malformations: feasibility study.

Authors:  Joachim Klisch; Lin Yin; Flavio Requejo; Barbara Eissner; Kai M Scheufler; Ralf Kubalek; Markus Buechner; Axel Pagenstecher; Heiner Nagursky; Martin Schumacher
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

Review 8.  Normal perfusion pressure breakthrough phenomenon: experimental models.

Authors:  Raquel Gutiérrez-González; Alvaro Pérez-Zamarron; Gregorio Rodríguez-Boto
Journal:  Neurosurg Rev       Date:  2014-04-29       Impact factor: 3.042

9.  Large animals in neurointerventional research: A systematic review on models, techniques and their application in endovascular procedures for stroke, aneurysms and vascular malformations.

Authors:  Andrea M Herrmann; Stephan Meckel; Matthew J Gounis; Leona Kringe; Edith Motschall; Christoph Mülling; Johannes Boltze
Journal:  J Cereb Blood Flow Metab       Date:  2019-02-07       Impact factor: 6.200

10.  Acute and chronic swine rete arteriovenous malformation models: hemodynamics and vascular remodeling.

Authors:  A K Wakhloo; B B Lieber; R Siekmann; D J Eber; M J Gounis
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.